Decoding and unlocking the BCL-2 dependency of cancer cells

Cancer cells are subject to many apoptotic stimuli that would kill them were it not for compensatory prosurvival alterations. BCL-2-like (BCL-2L) proteins contribute to such aberrant behaviour by engaging a network of interactions that is potent at promoting survival but that is also fragile: inhibition of a restricted number of interactions may suffice to trigger cancer cell death. Currently available and novel compounds that inhibit these interactions could be efficient therapeutic agents if this phenotype of BCL-2L dependence was better understood at a molecular, cellular and systems level and if it could be diagnosed by relevant biomarkers.

[1]  M. Hinds,et al.  Regulation of apoptosis: uncovering the binding determinants. , 2005, Current opinion in structural biology.

[2]  T. Kuwana,et al.  Sphingolipid Metabolism Cooperates with BAK and BAX to Promote the Mitochondrial Pathway of Apoptosis , 2012, Cell.

[3]  Gordon B Mills,et al.  Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. , 2012, Cancer cell.

[4]  G. Evan,et al.  Suppression of Myc-Induced Apoptosis in β Cells Exposes Multiple Oncogenic Properties of Myc and Triggers Carcinogenic Progression , 2002, Cell.

[5]  P. Marrack,et al.  The structure of a Bcl-xL/Bim fragment complex: implications for Bim function. , 2003, Immunity.

[6]  F. Zhong,et al.  Acidosis Promotes Bcl-2 Family-mediated Evasion of Apoptosis , 2012, The Journal of Biological Chemistry.

[7]  Z. Çakır,et al.  The C-terminal helix of Bcl-xL mediates Bax retrotranslocation from the mitochondria , 2012, Cell Death and Differentiation.

[8]  K. Jones,et al.  Activated Notch1 induces lung adenomas in mice and cooperates with Myc in the generation of lung adenocarcinoma. , 2011, Cancer research.

[9]  U. Moll,et al.  The mitochondrial p53 pathway. , 2009, Biochimica et biophysica acta.

[10]  R. Meadows,et al.  Structure of Bcl-xL-Bak Peptide Complex: Recognition Between Regulators of Apoptosis , 1997, Science.

[11]  J C Reed,et al.  Somatic Frameshift Mutations in the BAX Gene in Colon Cancers of the Microsatellite Mutator Phenotype , 1997, Science.

[12]  G. Evan,et al.  Modelling Myc inhibition as a cancer therapy , 2008, Nature.

[13]  A. Letai,et al.  Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML , 2012, Cell.

[14]  C. Croce,et al.  MicroRNA 29b functions in acute myeloid leukemia. , 2009, Blood.

[15]  S. Varambally,et al.  Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition , 2007, Proceedings of the National Academy of Sciences.

[16]  R. Schwarzenbacher,et al.  Membrane Remodeling Induced by the Dynamin-Related Protein Drp1 Stimulates Bax Oligomerization , 2010, Cell.

[17]  T. Chambers,et al.  Cdk1/cyclin B plays a key role in mitotic arrest-induced apoptosis by phosphorylation of Mcl-1, promoting its degradation and freeing Bak from sequestration. , 2012, Biochemical pharmacology.

[18]  G. Evan,et al.  c-Myc-induced sensitization to apoptosis is mediated through cytochrome c release. , 1999, Genes & development.

[19]  Wenhua Gao,et al.  Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. , 2003, Genes & development.

[20]  A. Petros,et al.  Rationale for Bcl‐XL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies , 2000, Protein science : a publication of the Protein Society.

[21]  M. Williams,et al.  Sequential bcl-2 and c-myc oncogene rearrangements associated with the clinical transformation of non-Hodgkin's lymphoma. , 1989, The Journal of clinical investigation.

[22]  P. Juin,et al.  Serum-Nutrient Starvation Induces Cell Death Mediated by Bax and Puma That Is Counteracted by p21 and Unmasked by Bcl-xL Inhibition , 2011, PloS one.

[23]  D. Andrews,et al.  Shedding Light on Apoptosis at Subcellular Membranes , 2012, Cell.

[24]  S. Korsmeyer,et al.  BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. , 2001, Molecular cell.

[25]  Michael T. Certo,et al.  Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. , 2007, The Journal of clinical investigation.

[26]  Sreenath V. Sharma,et al.  “Oncogenic Shock”: Turning an Activated Kinase against the Tumor Cell , 2006, Cell cycle.

[27]  S. Grant,et al.  Bim Upregulation by Histone Deacetylase Inhibitors Mediates Interactions with the Bcl-2 Antagonist ABT-737: Evidence for Distinct Roles for Bcl-2, Bcl-xL, and Mcl-1 , 2009, Molecular and Cellular Biology.

[28]  G. Dewson,et al.  Molecular biology of Bax and Bak activation and action. , 2011, Biochimica et biophysica acta.

[29]  V. Yee,et al.  Targeting Bcl-2 based on the interaction of its BH4 domain with the inositol 1,4,5-trisphosphate receptor. , 2009, Biochimica et biophysica acta.

[30]  Jochen H M Prehn,et al.  Systems analysis of BCL2 protein family interactions establishes a model to predict responses to chemotherapy. , 2013, Cancer research.

[31]  A. Strasser,et al.  Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases , 2011, The EMBO journal.

[32]  C. Akgul.  Mcl-1 is a potential therapeutic target in multiple types of cancer , 2009, Cellular and Molecular Life Sciences.

[33]  Alexei Degterev,et al.  A decade of caspases , 2003, Oncogene.

[34]  Erinna F. Lee,et al.  Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. , 2012, Genes & development.

[35]  C. Tse,et al.  ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. , 2008, Cancer research.

[36]  Nektarios Tavernarakis,et al.  Functional and physical interaction between Bcl‐XL and a BH3‐like domain in Beclin‐1 , 2007, The EMBO journal.

[37]  Yonghong Xiao,et al.  SCFFBW 7 regulates cellular apoptosis by targeting MCL 1 for ubiquitylation and destruction , 2011 .

[38]  D. Andrews,et al.  Differences in the mechanisms of proapoptotic BH3 proteins binding to Bcl-XL and Bcl-2 quantified in live MCF-7 cells. , 2012, Molecular cell.

[39]  D. L. Wilburn,et al.  Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. , 2008, Cancer research.

[40]  P. Cartron,et al.  Nonredundant Role of Bax and Bak in Bid-Mediated Apoptosis , 2003, Molecular and Cellular Biology.

[41]  Derek W. Yecies,et al.  Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. , 2010, Blood.

[42]  W. Wilson,et al.  Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. , 2012, Blood.

[43]  Richard W. Kriwacki,et al.  PUMA Binding Induces Partial Unfolding within BCL-xL to Disrupt p53 Binding and Promote Apoptosis , 2012, Nature chemical biology.

[44]  C. Tse,et al.  Bcl-2 family proteins are essential for platelet survival , 2007, Cell Death and Differentiation.

[45]  M. Warr,et al.  Unique biology of Mcl-1: therapeutic opportunities in cancer. , 2008, Current molecular medicine.

[46]  C. Croce,et al.  miR-15a and miR-16-1 in cancer: discovery, function and future perspectives , 2010, Cell Death and Differentiation.

[47]  Adam R. Johnson,et al.  Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7 , 2011, Nature.

[48]  W. Wilson,et al.  Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. , 2010, The Lancet. Oncology.

[49]  Z. Estrov,et al.  Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. , 2009, Blood.

[50]  L. Walensky,et al.  BH3-triggered structural reorganization drives the activation of proapoptotic BAX. , 2010, Molecular cell.

[51]  Nico Tjandra,et al.  Bcl-xL Retrotranslocates Bax from the Mitochondria into the Cytosol , 2011, Cell.

[52]  S. Korsmeyer,et al.  Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and Death , 2001, Science.

[53]  Hong-Gang Wang,et al.  Caspase-3-mediated cleavage of Rad9 during apoptosis , 2003, Oncogene.

[54]  Travis J Cohoon,et al.  Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. , 2013, Cancer cell.

[55]  M. Hung,et al.  Degradation of Mcl-1 by β-TrCP Mediates Glycogen Synthase Kinase 3-Induced Tumor Suppression and Chemosensitization , 2006, Molecular and Cellular Biology.

[56]  P. Bornstein,et al.  TOM22, a core component of the mitochondria outer membrane protein translocation pore, is a mitochondrial receptor for the proapoptotic protein Bax , 2007, Cell Death and Differentiation.

[57]  L. Pevny,et al.  Human embryonic stem cells have constitutively active Bax at the Golgi and are primed to undergo rapid apoptosis. , 2012, Molecular cell.

[58]  Erinna F. Lee,et al.  Bax Crystal Structures Reveal How BH3 Domains Activate Bax and Nucleate Its Oligomerization to Induce Apoptosis , 2013, Cell.

[59]  D. Andrews,et al.  Membrane Binding by tBid Initiates an Ordered Series of Events Culminating in Membrane Permeabilization by Bax , 2008, Cell.

[60]  C. Dive,et al.  Hypoxic human cancer cells are sensitized to BH-3 mimetic–induced apoptosis via downregulation of the Bcl-2 protein Mcl-1. , 2011, The Journal of clinical investigation.

[61]  Erinna F. Lee,et al.  Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. , 2012, Blood.

[62]  S. Korsmeyer,et al.  Obligate Role of Anti-Apoptotic MCL-1 in the Survival of Hematopoietic Stem Cells , 2005, Science.

[63]  William Arbuthnot Sir Lane,et al.  N-terminal Truncation of Antiapoptotic MCL1, but Not G2/M-induced Phosphorylation, Is Associated with Stabilization and Abundant Expression in Tumor Cells* , 2007, Journal of Biological Chemistry.

[64]  S. Korsmeyer,et al.  Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1 , 2003, Nature.

[65]  Hao Xiong,et al.  Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  D. McMillin,et al.  Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition. , 2007, The Journal of clinical endocrinology and metabolism.

[67]  L. Beverly.  Regulation of anti‐apoptotic BCL2‐proteins by non‐canonical interactions: The next step forward or two steps back? , 2012, Journal of cellular biochemistry.

[68]  A. Strasser,et al.  Endogenous Bcl-xL is essential for Myc-driven lymphomagenesis in mice. , 2011, Blood.

[69]  S. Korsmeyer,et al.  Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair , 1993, Cell.

[70]  L. Lam,et al.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets , 2013, Nature Medicine.

[71]  L. Walensky,et al.  Direct and selective small-molecule activation of proapoptotic BAX. , 2012, Nature chemical biology.

[72]  Erinna F. Lee,et al.  The role of BH3-only protein Bim extends beyond inhibiting Bcl-2–like prosurvival proteins , 2009, The Journal of cell biology.

[73]  P. Juin,et al.  pRb/E2F-1-mediated caspase-dependent induction of Noxa amplifies the apoptotic effects of the Bcl-2/Bcl-xL inhibitor ABT-737 , 2013, Cell Death and Differentiation.

[74]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[75]  M. Hinds,et al.  Structural plasticity underpins promiscuous binding of the prosurvival protein A1. , 2008, Structure.

[76]  Philippe Juin,et al.  The first alpha helix of Bax plays a necessary role in its ligand-induced activation by the BH3-only proteins Bid and PUMA. , 2004, Molecular cell.

[77]  D. Green,et al.  Resistance to caspase-independent cell death requires persistence of intact mitochondria. , 2010, Developmental cell.

[78]  Erinna F. Lee,et al.  Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family , 2007, Cell Death and Differentiation.

[79]  A. Letai,et al.  The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance , 2011, Cell Death and Disease.

[80]  Emiko Fire,et al.  The MCL-1 BH3 Helix is an Exclusive MCL-1 inhibitor and Apoptosis Sensitizer , 2010, Nature chemical biology.

[81]  David E. Housman,et al.  mTORC1 promotes survival through translational control of Mcl-1 , 2008, Proceedings of the National Academy of Sciences.

[82]  M. Campone,et al.  c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1 , 2011, Molecular Cancer.

[83]  P. Ekert,et al.  Programmed Anuclear Cell Death Delimits Platelet Life Span , 2007, Cell.

[84]  Derek Y. Chiang,et al.  The landscape of somatic copy-number alteration across human cancers , 2010, Nature.

[85]  John Calvin Reed,et al.  Structure-function comparisons of the proapoptotic protein Bax in yeast and mammalian cells , 1996, Molecular and cellular biology.

[86]  N. Tjandra,et al.  BAX Activation is Initiated at a Novel Interaction Site , 2008, Nature.

[87]  Erinna F. Lee,et al.  Structural insights into the degradation of Mcl-1 induced by BH3 domains , 2007, Proceedings of the National Academy of Sciences.

[88]  Ji Luo,et al.  Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction , 2009, Cell.

[89]  Ben S. Wittner,et al.  Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.

[90]  G. Giaccone,et al.  Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer , 2012, Clinical Cancer Research.

[91]  P. Colman,et al.  BCL-2 family antagonists for cancer therapy , 2008, Nature Reviews Drug Discovery.

[92]  G. Gores,et al.  Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors. , 2012, Genes & development.

[93]  J. Opferman,et al.  A competitive stapled peptide screen identifies a selective small molecule that overcomes MCL-1-dependent leukemia cell survival. , 2012, Chemistry & biology.

[94]  Andrew L. Kung,et al.  Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency. , 2012, Cancer cell.

[95]  D. Green,et al.  A unified model of mammalian BCL-2 protein family interactions at the mitochondria. , 2011, Molecular cell.

[96]  C. Scott,et al.  The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. , 2006, Cancer cell.

[97]  G. Gillet,et al.  Non-apoptotic roles of Bcl-2 family: the calcium connection. , 2013, Biochimica et biophysica acta.

[98]  Patricia Greninger,et al.  A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. , 2009, Cancer cell.

[99]  David A Hildeman,et al.  ×Phosphorylation of Bax Ser184 by Akt Regulates Its Activity and Apoptosis in Neutrophils* , 2004, Journal of Biological Chemistry.

[100]  Jian Yu,et al.  PUMA, a potent killer with or without p53 , 2008, Oncogene.

[101]  T. Kuwana,et al.  BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. , 2005, Molecular cell.

[102]  J. Hickman,et al.  Bax activation by the BH3-only protein Puma promotes cell dependence on antiapoptotic Bcl-2 family members , 2009, The Journal of cell biology.

[103]  M. Butterworth,et al.  Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. , 2009, Blood.

[104]  Brian J. Smith,et al.  Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. , 2005, Molecular cell.

[105]  D. Saur,et al.  Translational Repression of MCL-1 Couples Stress-induced eIF2α Phosphorylation to Mitochondrial Apoptosis Initiation* , 2007, Journal of Biological Chemistry.

[106]  P. Fisher,et al.  Targeting Mcl-1 for the therapy of cancer , 2011, Expert opinion on investigational drugs.

[107]  S. Barillé-Nion,et al.  Regulation of cancer cell survival by BCL2 family members upon prolonged mitotic arrest: opportunities for anticancer therapy. , 2012, Anticancer research.

[108]  P. Hegde,et al.  A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[109]  F. Bazan,et al.  Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival , 2010, Nature.

[110]  S. R. Datta,et al.  Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death Machinery , 1997, Cell.

[111]  Seamus J. Martin,et al.  Oncogenic Ras-induced expression of Noxa and Beclin-1 promotes autophagic cell death and limits clonogenic survival. , 2011, Molecular cell.

[112]  Xiaodong Wang,et al.  Mule/ARF-BP1, a BH3-Only E3 Ubiquitin Ligase, Catalyzes the Polyubiquitination of Mcl-1 and Regulates Apoptosis , 2005, Cell.

[113]  P. Cartron,et al.  Prostaglandins antagonistically control Bax activation during apoptosis , 2011, Cell Death and Differentiation.

[114]  J. Hickman,et al.  Bax Activation by Engagement with, Then Release from, the BH3 Binding Site of Bcl-xL , 2010, Molecular and Cellular Biology.

[115]  P. Juin,et al.  Escape from p21-mediated Oncogene-induced Senescence Leads to Cell Dedifferentiation and Dependence on Anti-apoptotic Bcl-xL and MCL1 Proteins* , 2011, The Journal of Biological Chemistry.

[116]  J. Nordenström.  The calcium connection , 2013 .

[117]  A. Petros,et al.  Structural biology of the Bcl-2 family of proteins. , 2004, Biochimica et biophysica acta.

[118]  Mari Nishino,et al.  Proapoptotic BAX and BAK regulate the type 1 inositol trisphosphate receptor and calcium leak from the endoplasmic reticulum. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[119]  K. Glaser,et al.  Bcl-XL represents a druggable molecular vulnerability during aurora B inhibitor-mediated polyploidization , 2010, Proceedings of the National Academy of Sciences.

[120]  R. Houtkooper,et al.  MTCH2/MIMP is a major facilitator of tBID recruitment to mitochondria , 2010, Nature Cell Biology.

[121]  S. Lowe,et al.  Intrinsic tumour suppression , 2004, Nature.

[122]  D. Green,et al.  Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. , 2006, Molecular cell.

[123]  D. Andrews,et al.  Bcl-XL Inhibits Membrane Permeabilization by Competing with Bax , 2008, PLoS biology.

[124]  S. Korsmeyer,et al.  Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. , 2002, Cancer cell.

[125]  A. Letai,et al.  Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy , 2011, Science.